Iteos Therapeutics — Investor Presentation (January 2024)
27 slides from Iteos Therapeutics's investor presentation, Jan 10, 2024
Slide 1: Cancer Immunotherapies by design
Cancer Immunotherapies by design™ Nasdaq: ITOS January 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possib
Slide 3: A Defining Year for iTeos
Promising TIGIT:PD-1 Doublet 1 2024 Two Data Readouts Anticipated in 2024 A Defining Year Unlocking Adenosine Pathway 2 for iTeos Two Data Readouts Anticipated in 2024 Funded Through 2026 3 $645M in cash as of 3Q23 iteostherapeutics.com 3
Slide 4: Deep Pipeline with Four Clinical Readouts in 2024
Deep Pipeline with Four Clinical Readouts in 2024 Innovative molecules and compelling combinations Preclinical Phase 1 Phase 2 Phase 3 Status Belrestotug: IgG1 antibody targeting TIGIT + dostarlimab | 1L NSCLC PDLI high Planned Study + dostarlimab | 1L NSCLC PDL1high GALAXIES Lung-201 Data Anticipat
Slide 5: Belrestotug
Belrestotug EOS-448 / GSK4428859A iTeos and GSK are uniquely positioned to leverage the TIGIT/CD226 axis iteostherapeutics.com 5
Slide 6: Advantageous Field Position
We Hold An Validation of Indication Selection Advantageous TIGIT as a Target Importance Field Position Significant momentum in 2023 Quality of Optimizing Components Trial Design Matters iteostherapeutics.com 6
Slide 7: There Is A Need for a Transformative TIGIT:PD-1 Doublet
There Is A Need for a Transformative TIGIT:PD-1 Doublet We Believe Our TIGIT:PD-1 Doublet Is Differentiating In Key Areas High Quality PD-1 Proven quality target engagement with TIGIT and FcγR TIGIT monotherapy activity Pembrolizumab comparison High Quality TIGIT iteostherapeutics.com 7
Slide 8: The Need for a Transformative TIGIT:PD-1 Doublet
The Need for a Transformative TIGIT:PD-1 Doublet Belrestotug + dostarlimab represent differentiated, high-quality therapies Phase 1 3 Negative Limited Data Strong POC Monotherapy ESMO Fc Silent Disclosed with SKY-012 Activity1 Readouts3 Dostarlimab Market No Pembro No Pembro No Pembro PERLA Data4 Le
Slide 9: Belrestotug: The First And Only TIGIT to Demonstrate Robust Target Engagement
Belrestotug: The First And Only TIGIT to Demonstrate Robust Target Engagement TIGIT+ Treg Depletion in Patients Unique Epitope Binding 100% High Affinity + Potency 80% First and only TIGIT with proven Treg depletion at all doses 20-30%2 1 Not observed3 Undisclosed* Fc Silent* 0% Only TIGIT to Demons
Slide 10: PERLA: Dostarlimab Is A Quality Anti-PD-1 Backbone
PERLA: Dostarlimab Is A Quality Anti-PD-1 Backbone Positive numerical OS trend in 1L NSCLC favoring dostarlimab + CT vs. pembrolizumab + CT Phase 2 PERLA Study1 Median OS Dostarlimab + CT: 19.4 months (95% CI: 14.5–NR) Pembrolizumab + CT: 15.9 months (95% CI: 11.6–19.3) HR 0.75 (95% CI: 0.53–1.05) O
Slide 11: SKY-01: Meaningful Separation of Curves Validates TIGIT
SKY-01: Meaningful Separation of Curves Validates TIGIT Quality of components and clinical trial design leave room for improvement Phase 3 SKY-01 IA21 in 1L NSCLC Key Insights 1. Validated TIGIT as a target with mOS extended by ~6 months 2. Robust study design could Median OS provide meaningful effi
Slide 12: GALAXIES Lung-201 - Phase 2 in 1L NSCLC
GALAXIES Lung-201 - Phase 2 in 1L NSCLC The largest TIGIT Phase 2 in 1L NSCLC Pembrolizumab LUNG-201 Dostarlimab Dostarlimab + Belrestotug (Dose A) Dostarlimab + Belrestotug (Dose B) Dostarlimab + Belrestotug (Dose C) Dostarlimab + Belrestotug + GSK’608 (CD96) Study Design Estimated Enrollment 300 S
Slide 13: 1L NSCLC: Building A Meaningful Position
1L NSCLC: Building A Meaningful Position Evolving competitive landscape favoring a high-quality TIGIT:PD-1 doublet Strong scientific rationale with high levels of 31k TIGIT+ Tregs, high infiltration of T cells, and highly amenable to IO therapies The right Phase 3 strategy with right dose, right com
Slide 14: GALAXIES H&N-202: Phase 2 in 1L HNSCC
GALAXIES H&N-202: Phase 2 in 1L HNSCC Dostarlimab H&N-202 Dostarlimab + Belrestotug Dostarlimab + GSK’608 (CD96) Dostarlimab + Belrestotug + GSK’608 (CD96) Study Design Estimated Enrollment 360 Status Enrolling Objectives Evaluate antitumor activity, safety of Dostarlimab + novel IOs Masking Open la
Slide 15: TIG-006 – Phase 2 in 1L HNSCC PDL1 High/Low
TIG-006 – Phase 2 in 1L HNSCC PDL1High/Low Dostarlimab + CPS High ≥ 20 Belrestotug (Dose B) Dostarlimab + CPS Low < 20 Belrestotug (Dose B) Study Design Estimated Enrollment 80 Status Enrolling Objectives Evaluate Belrestotug + Dostarlimab in two CPS populations Masking Open label Primary Endpoint O
Slide 16: 1L HNSCC: Potential First-to-Market Opportunity
1L HNSCC: Potential First-to-Market Opportunity Under-served population with strong biological rationale seeking advances Strong scientific rationale with high levels of 17k TIGIT+ Tregs, high infiltration of T cells and the indication being amenable to PD-1 therapy Significant market opportunity du
Slide 17: Belrestotug + Dostarlimab Are Uniquely Positioned to Fully Exploit TIGIT Pathway
Belrestotug + Dostarlimab Are Uniquely Positioned to Fully Exploit TIGIT Pathway Novel Unique Biomarker IO Sensitive Combinations Tumors 1L NSCLC Foundation Expansion Design Implementation 1L NSCLC to serve as launch Target clinically validated Utilize doublets beyond Integrate promising TIGIT point
Slide 18: The Right Deal & The Right Partner
The Right Deal & The Right Partner Data-driven approach to unlock potential of high-quality regimens Success Factors Payments $625M upfront, up to $1.45B milestones Territories US: co-commercialization Quality TIGIT Proven PD-1 and 50/50 profit share Ex-US: double digit royalties up to 20% Developme
Slide 19: Adenosine Pathway
Adenosine Pathway Unlocking one of the most promising targets responsible for immunosuppression iteostherapeutics.com 19
Slide 20: Addressing The Critical Adenosine Pathway Issue
Addressing The Critical Adenosine Pathway Issue: Adenosine Inhibits Immune Cell Activity + Proliferation Adenosine Inupadenant: Best-in-Class Approach • Targets A2AR, restoring immune cell activity, specifically Plasma cell T cell plasma cell antibody production • First and only A2AR antagonist to m
Slide 21: Inupadenant: A Class of Its Own
Inupadenant: A Class of Its Own Best-in-class, highly selective A2AR antagonist optimized for hostile solid TME Adenosine A2AR Targeting A2AR (unable to bind) • A2AR activation by adenosine suppresses immune cell responses, inhibiting anti-tumor response Tumor cell death • Inupadenant targets A2AR,
Slide 22: A2A-005: Phase 2 in 2L NSCLC (Post-IO) Chemo-Naïve
A2A-005: Phase 2 in 2L NSCLC (Post-IO) Chemo-Naïve Key R Subjects Randomization Inupadenant + Carboplatin / n=75 Pemetrexed Inupadenant (80mg) + Carboplatin / Pemetrexed Inupadenant (60mg) + Carboplatin / Pemetrexed R Inupadenant (40mg) + Carboplatin / Pemetrexed n=75 Carboplatin / Pemetrexed Study
Slide 23: Inupadenant Counteracts Chemotherapy's Key Downfall
Inupadenant Counteracts Chemotherapy’s Key Downfall 2L NSCLC is an under-served population with strong biological rationale seeking advances Chemotherapy increases adenosine levels 15k via cell death, hindering the immune system and plasma cell activity Inupadenant maintains potency + function at hi
Slide 24: EOS-984: Enhancing T Cell Proliferation in the Hostile TME
EOS-984: Enhancing T Cell Proliferation in the Hostile TME One of the most meaningful discoveries in the adenosine pathway Intracellular adenosine uptake The Role of ENT1 ENT1 • Dominant transporter of adenosine on lymphocytes effecting: Inflammation, cell death Tumor cell proliferation High levels
Slide 25: EOS-984: Phase 1 in Advanced Solid Tumors
EOS-984: Phase 1 in Advanced Solid Tumors Evaluation of target engagement and impact on T cells in TME EOS-984 (30mg) EOS-984 (RP2D)+ EOS-984 (22.5mg) Pembrolizumab (200mg) EOS-984 (RP2D -1) + EOS-984 (15mg) RP2D Pembrolizumab (200mg) EOS-984 (10mg) EOS-984 (RP2D -2) + Pembrolizumab (200mg) EOS-984
Slide 26: 2024: Pivotal Year of Data Generation
2024: Pivotal Year of Data Generation Innovative portfolio leveraging deep tumor immunology expertise Funded Through TIGIT Adenosine Pathway Significant Milestones 1L NSCLC A2AR - 2L NSCLC $645M As of 3Q23 (Phase 2 GALAXIES LUNG-201) (Phase 2 A2A-005) 1L HNSCC ENT1 - MOA In cash, cash equivalents an
Slide 27: Cancer Immunotherapies by design
Cancer Immunotherapies by design™ Nasdaq: ITOS January 2024
iTeos Therapeutics — Investor Presentation (January 2024) on 6ix